Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 331-340 of 541 for

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. LEGEND Study: EG-70 In NMIBC Patients BCG-Unresponsive And High-Risk NMIBC Incompletely Treated With BCG Or BCG-Naïve

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

    Jacksonville, FL

  3. An Investigational Scan (Ga-68 PSMA-11 PET/CT) For Detection Of Disease Recurrence Or Progression In Patients With Glioma

    Rochester, MN

  4. Therapeutic Plasma Exchange With Enfortumab Vedotin And Pembrolizumab For Treatment Of Bladder Cancers

    Rochester, MN

  5. In-home Intravesical Chemotherapy For The Treatment Of Bladder Cancer, INVITE Trial

    Jacksonville, FL

  6. A Study Of Abenacianine (VGT-309) To Identify Cancer When Undergoing Surgery For Cancer In The Lung

    Rochester, MN

  7. Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

    Rochester, MN, Rochester, MN

  8. PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination with Anti-PD-1/L1 in Patients with Locally Advanced or Metastatic Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. INCB161734 For Advanced Or Metastatic Solid Tumors With KRAS G12D Mutation

    Scottsdale/Phoenix, AZ

  10. A Study to Evaluate the Safety and Effectiveness of Lisocatagene Maraleucel in Patients

    Rochester, MN, Jacksonville, FL

.

Mayo Clinic Footer